GAO Says Feds Don't Have Patent Rights To Remdesivir
The U.S. government doesn't have the rights to patents covering Gilead Science Inc.'s experimental antiviral drug remdesivir, the Government Accountability Office said Wednesday, noting that although taxpayers spent $162 million on...To view the full article, register now.
Already a subscriber? Click here to view full article